115.85 +0.04 (0.03%)
Pre-market: 8:33AM EDT
Is (ABBV) Outperforming Other Medical Stocks This Year?
AbbVie (ABBV) closed at $113.98 in the latest trading session, marking a -0.61% move from the prior day.
Despite launching nearly two decades ago, worldwide sales of AbbVie's (NYSE: ABBV) lead drug, Humira still generates more revenue than most countries. As you can imagine, patent-protected exclusivity expected to expire in the U.S. in 2023 has been a major concern for AbbVie for a long time. In fact, eight years ago, Abbott spun out its biopharmaceutical segment into a separate company to protect the parent from Humira's impending patent cliff.